XML 37 R13.htm IDEA: XBRL DOCUMENT v3.20.1
Stock Based Compensation
9 Months Ended
Mar. 31, 2020
Stock Based Compensation  
Note 7 - Stock Based Compensation

The equity incentive plan of the Company was established in February of 2017. The Board of Directors of the Company may from time to time, in its discretion grant to directors, officers, consultants and employees of the Company, non-transferable options to purchase common shares, provided that the number of options issued do not exceed 20,000,000. The options are exercisable for a period of up to 10 years from the date of the grant. The number of shares authorized to be issued under the equity incentive plan was increased from 10,000,000 to 20,000,000 through a consent of stockholders to amend and restate the equity incentive plan. 

   

The following table reflects the continuity of stock options for the nine months ended March 31, 2020:

 

A summary of stock option activity is as follows:

 

 

March 31,

2020

 

Number of options outstanding:

 

Beginning of year

 

4,598,823

 

Granted

 

9,990,875

 

Exercised, converted

 

-

 

Forfeited / exchanged / modification

 

(4,571,823

)

 

End of period

 

10,017,875

 

Number of options exercisable at end of period

 

27,000

 

Number of options available for grant at end of period

 

9,982,125

 

Weighted average option prices per share:

 

Granted during the period

 

$

0.07

 

Exercised during the period

 

$

0.00

 

Terminated during the period

 

$

0.45

 

Outstanding at end of period

 

$

0.71

 

Exercisable at end of period

 

$

0.71

 

Stock-based compensation expense attributable to stock options and stock grants was approximately $711,511 for the nine-month period ended March 31, 2020. As of March 31, 2020, there was approximately $6,509 of unrecognized compensation expense related to unvested stock options outstanding, and the weighted average vesting period for those options was 3 years.

  

Warrants

 

At March 31, 2020, the Company had outstanding warrants to purchase the Company’s common stock which were issued in connection with multiple financing arrangements. Information relating to these warrants is summarized as follows:

 

Warrants

 

Remaining

Number

Outstanding

 

Weighted

Average

Remaining Life (Years)

 

Weighted

Average

Exercise Price

 

Warrants-Financing

 

86,957

 

3.05

 

$

1.15

 

Warrants-Issued with Convertible Notes

 

600,000

 

3.48

 

$

0.75

 

Warrants – Financing

 

360,577

 

4.27

 

$

0.78

 

Warrants A – Financing

 

7,018,090

 

.27

 

0.16

 

Warrants B – Financing

 

28,072,364

 

4.27

 

$

0.16

 

Total

 

36,137,988